New insider activity at Gilead Sciences ( (GILD) ) has taken place on December 1, 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Director Jeffrey Bluestone has recently sold 5,000 shares of Gilead Sciences stock, amounting to a total transaction value of $625,400.
Spark’s Take on GILD Stock
According to Spark, TipRanks’ AI Analyst, GILD is a Outperform.
Gilead Sciences’ strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. The company’s robust profitability, effective cash flow management, and strategic advancements in its HIV portfolio contribute significantly to its attractiveness. Technical indicators support a generally positive outlook, though some caution is warranted due to potential overbought conditions. The valuation is fair, making the stock appealing for both growth and income investors.
To see Spark’s full report on GILD stock, click here.
More about Gilead Sciences
YTD Price Performance: 39.13%
Average Trading Volume: 7,350,900
Technical Sentiment Signal: Buy
Current Market Cap: $156.1B